Document is current
Any future updates will be listed below
-
Authors
d’Escamard, Valentina
Kadian-Dodov, Daniella
Ma, Lijiang
Lu, Sizhao https://orcid.org/0000-0002-9892-8784
King, Annette
Xu, Yang https://orcid.org/0000-0003-4669-0003
Peng, Shouneng https://orcid.org/0000-0002-8812-6438
V′Gangula, Bhargravi
Zhou, Yu
Thomas, Allison
Michelis, Katherine C.
Bander, Emir
Bouchareb, Rihab
Georges, Adrien https://orcid.org/0000-0003-4208-2393
Nomura-Kitabayashi, Aya https://orcid.org/0000-0001-7733-5122
Wiener, Robert J. https://orcid.org/0000-0001-5238-1659
Costa, Kevin D.
Chepurko, Elena
Chepurko, Vadim
Fava, Marika
Barwari, Temo https://orcid.org/0000-0003-2279-8677
Anyanwu, Anelechi
Filsoufi, Farzan
Florman, Sander
Bouatia-Naji, Nabila https://orcid.org/0000-0001-5424-2134
Schmidt, Lukas E. https://orcid.org/0000-0001-7565-1455
Mayr, Manuel
Katz, Michael G.
Hao, Ke https://orcid.org/0000-0002-1815-9197
Weiser-Evans, Mary C. M. https://orcid.org/0000-0002-6239-2412
Björkegren, Johan L. M. https://orcid.org/0000-0003-1945-7425
Olin, Jeffrey W. https://orcid.org/0000-0003-3374-616X
Kovacic, Jason C. https://orcid.org/0000-0003-4555-769X
- License Information
-
More Information
Article History
Received: 18 November 2022
Accepted: 31 July 2024
First Online: 13 September 2024
Competing interests
: J.C.K. is the recipient of an Agilent Thought Leader Award (January 2022), which includes funding for research that is unrelated to the current manuscript. K.D.C. (a co-investigator in this study) is the scientific co-founder of, receives financial compensation as the chief scientific officer for and holds equity in NovoHeart LTD (a biotechnology company that focuses on using human stem cells and engineered human cardiac tissues for drug development/screening applications). The other authors declare no competing interests.
